Protein structure similarity clustering (PSSC) and natural product structure as inspiration sources for drug development and chemical genomics.

Finding small molecules that modulate protein function is of primary importance in drug development and in the emerging field of chemical genomics. To facilitate the identification of such molecules, we developed a novel strategy making use of structural conservatism found in protein domain architecture and natural product inspired compound library design. Domains and proteins identified as being structurally similar in their ligand-sensing cores are grouped in a protein structure similarity cluster (PSSC). Natural products can be considered as evolutionary pre-validated ligands for multiple proteins and therefore natural products that are known to interact with one of the PSSC member proteins are selected as guiding structures for compound library synthesis. Application of this novel strategy for compound library design provided enhanced hit rates in small compound libraries for structurally similar proteins.

[1]  C Sander,et al.  Mapping the Protein Universe , 1996, Science.

[2]  H. Waldmann,et al.  Natural Product-derived Compound Libraries and Protein Structure Similarity as Guiding Principles for the Discovery of Drug Candidates , 2004 .

[3]  A. M. Boldi,et al.  Libraries from natural product-like scaffolds. , 2004, Current opinion in chemical biology.

[4]  H. Kubinyi,et al.  A scoring scheme for discriminating between drugs and nondrugs. , 1998, Journal of medicinal chemistry.

[5]  S. Schreiber,et al.  Target-oriented and diversity-oriented organic synthesis in drug discovery. , 2000, Science.

[6]  C. Lanni,et al.  Acetylcholinesterase inhibitors: novel activities of old molecules. , 2004, Pharmacological research.

[7]  Stuart L Schreiber,et al.  A planning strategy for diversity-oriented synthesis. , 2004, Angewandte Chemie.

[8]  John Moult,et al.  A unifold, mesofold, and superfold model of protein fold use , 2002, Proteins.

[9]  B. E. Evans,et al.  Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of Medicinal Chemistry.

[10]  Robert B Russell,et al.  Finding functional sites in structural genomics proteins. , 2004, Structure.

[11]  S. Frye.  Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era. , 1999, Chemistry & biology.

[12]  H. Waldmann,et al.  Natural products are biologically validated starting points in structural space for compound library development: solid-phase synthesis of dysidiolide-derived phosphatase inhibitors. , 2002, Angewandte Chemie.

[13]  P E Bourne,et al.  Protein structure alignment by incremental combinatorial extension (CE) of the optimal path. , 1998, Protein engineering.

[14]  E. Fauman,et al.  Crystal Structure of the Catalytic Domain of the Human Cell Cycle Control Phosphatase, Cdc25A , 1998, Cell.

[15]  A. Odermatt,et al.  A rapid screening assay for inhibitors of 11β-hydroxysteroid dehydrogenases (11β-HSD): flavanone selectively inhibits 11β-HSD1 reductase activity , 2003, Molecular and Cellular Endocrinology.

[16]  E. Koonin,et al.  The structure of the protein universe and genome evolution , 2002, Nature.

[17]  H. Waldmann,et al.  Inhibitors of protein tyrosine phosphatases: next-generation drugs? , 2005, Angewandte Chemie.

[18]  G. Müller,et al.  Medicinal chemistry of target family-directed masterkeys. , 2003, Drug discovery today.

[19]  A Ganesan,et al.  Natural products as a hunting ground for combinatorial chemistry. , 2004, Current opinion in biotechnology.

[20]  C. Chothia,et al.  Evolution of the Protein Repertoire , 2003, Science.

[21]  S. Wang,et al.  Leukotriene A4 hydrolase as a target for cancer prevention and therapy. , 2004, Current cancer drug targets.

[22]  Ian J. Deary,et al.  11β-Hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics , 2004 .

[23]  M. Kelly-Borges,et al.  Dysidiolide: A Novel Protein Phosphatase Inhibitor from the Caribbean Sponge Dysidea etheria de Laubenfels , 1996 .

[24]  David J Newman,et al.  Natural products as sources of new drugs over the period 1981-2002. , 2003, Journal of natural products.

[25]  I. Arkin,et al.  Monte Carlo estimation of the number of possible protein folds: Effects of sampling bias and folds distributions , 2003, Proteins.

[26]  P. Wipf,et al.  Dual-specificity phosphatases as targets for antineoplastic agents , 2002, Nature Reviews Drug Discovery.

[27]  Sally Rose.  Statistical design and application to combinatorial chemistry. , 2002, Drug discovery today.

[28]  C. Ponting,et al.  Evolution of domain families. , 2000, Advances in protein chemistry.

[29]  F. Fitzpatrick,et al.  Leukotriene A4 hydrolase. Inhibition by bestatin and intrinsic aminopeptidase activity establish its functional resemblance to metallohydrolase enzymes. , 1991, The Journal of biological chemistry.

[30]  M J Sternberg,et al.  Supersites within superfolds. Binding site similarity in the absence of homology. , 1998, Journal of molecular biology.

[31]  Ajay,et al.  Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? , 1998, Journal of medicinal chemistry.

[32]  I. Ollmann,et al.  Amino hydroxamic acids as potent inhibitors of leukotriene A4 hydrolase. , 1995, Bioorganic & medicinal chemistry.

[33]  Herbert Waldmann,et al.  Protein Structure Similarity as Guiding Principle for Combinatorial Library Design , 2003, Biological chemistry.

[34]  B. Stockwell,et al.  Biological mechanism profiling using an annotated compound library. , 2003, Chemistry & biology.

[35]  Herbert Waldmann,et al.  Protein structure similarity clustering and natural product structure as guiding principles in drug discovery. , 2005, Drug discovery today.

[36]  J. Flier,et al.  A Transgenic Model of Visceral Obesity and the Metabolic Syndrome , 2001, Science.

[37]  Sarah A. Teichmann,et al.  An insight into domain combinations , 2001, ISMB.

[38]  Hugo Kubinyi,et al.  Chemogenomics in Drug Discovery: A Medicinal Chemistry Perspective , 2004 .

[39]  H. Waldmann,et al.  Solid-phase synthesis of dysidiolide-derived protein phosphatase inhibitors. , 2002, Journal of the American Chemical Society.

[40]  B. Walker,et al.  11β-Hydroxysteroid dehydrogenase Type 1 as a novel therapeutic target in metabolic and neurodegenerative disease , 2003, Expert opinion on therapeutic targets.

[41]  M. New,et al.  Steroid disorders in children: congenital adrenal hyperplasia and apparent mineralocorticoid excess. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Burkhard Rost,et al.  Domains, motifs and clusters in the protein universe. , 2003, Current opinion in chemical biology.

[43]  E. Gulve,et al.  Chemistry and biochemistry of type 2 diabetes. , 2004, Chemical reviews.

[44]  Philip E. Bourne,et al.  A database and tools for 3-D protein structure comparison and alignment using the Combinatorial Extension (CE) algorithm , 2001, Nucleic Acids Res..

[45]  David A. Lee,et al.  Progress towards mapping the universe of protein folds , 2004, Genome Biology.

[46]  Chi‐Huey Wong,et al.  Development of selective tight-binding inhibitors of leukotriene A4 hydrolase. , 1993, Journal of medicinal chemistry.

[47]  Ajay,et al.  Recognizing molecules with drug-like properties. , 1999, Current opinion in chemical biology.

[48]  Herbert Waldmann,et al.  Compound library development guided by protein structure similarity clustering and natural product structure. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Irwin D Kuntz,et al.  Small molecule affinity fingerprinting. A tool for enzyme family subclassification, target identification, and inhibitor design. , 2002, Chemistry & biology.

[50]  N. Grishin.  Fold change in evolution of protein structures. , 2001, Journal of structural biology.

[51]  Nikolay P Savchuk,et al.  Exploring the chemogenomic knowledge space with annotated chemical libraries. , 2004, Current opinion in chemical biology.

[52]  G. Chrousos.  Is 11beta-hydroxysteroid dehydrogenase type 1 a good therapeutic target for blockade of glucocorticoid actions? , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Herbert Waldmann,et al.  From protein domains to drug candidates-natural products as guiding principles in the design and synthesis of compound libraries. , 2002, Angewandte Chemie.